Stockpolly
Search
PYPD · NASDAQ · Biotechnology

PolyPid (PYPD)

Develops local prolonged-release therapies led by D-PLEX100 for surgical-site infection prevention.

$5.28
At close−0.05 (−0.94%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
566678897−98−8
Research & development455567665666
111111132222
Selling & marketing000000010100
General & administrative111111122221
Other expenses000000000−170−16
Operating income−5−6−6−6−7−8−8−9−79−88
000000−1−10−170−16
Interest income000000000000
Interest expense000000110000
Other non-operating income00000000017016
Income before tax−6−6−6−6−8−9−8−10−7−9−8−8
Income tax expense000000000000
Net income from continuing operations−6−6−6−6−8−9−8−10−7−8−8−8
Net income−6−6−6−6−8−9−8−10−7−8−8−8
EPS, basic−$3.40−$3.84−$1.37−$1.25−$1.22−$1.13−$0.70−$0.78−$0.37−$0.41−$0.35−$0.35
EPS, diluted−$3.40−$3.84−$1.37−$1.25−$1.22−$1.13−$0.70−$0.78−$0.37−$0.41−$0.35−$0.35
Weighted average shares, basic225568121320212223
Weighted average shares, diluted225568121320212223
EBITDA−5−6−6−6−7−8−8−9−7−8−8−7
Depreciation & amortization000000000000
EBIT−5−6−6−6−7−8−8−9−7−9−8−8